J Mult Scler Neuroimmunol.
2024 Jun;15(1):31-34. 10.59578/jmsni.2024.15.1.31.
Severe Neutropenia Following Rituximab Treatment in Patients with Multiple Sclerosis
- Affiliations
-
- 1Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea
- 2Department of Neurology, Inje University Sanggye Paik Hospital, Seoul, Korea
- KMID: 2562000
- DOI: http://doi.org/10.59578/jmsni.2024.15.1.31
Abstract
- Increasing evidence suggests that B cells play a critical role in the pathogenesis of multiple sclerosis (MS). Rituximab (RTX), a monoclonal anti-CD20 antibody, effectively decreases inflammatory disease processes in patients with MS by specifically removing B cells. Neutropenia is an uncommon side effect of CD20-depleting treatment and may require the administration of granulocyte-colony stimulating factors. We report the case of a patient with MS who experienced severe neutropenia during RTX treatment.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Rituximab Treatment for Neuroimmunologic Disorders
- Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea
- Three Cases of Rituximab Treatment for Orbital Inflammatory Disease
- A Case of Atypical Kawasaki Disease with Severe Neutropenia
- Late-onset Neutropenia Following Rituximab Therapy as a Treatment of Diffuse Large B-cell Lymphoma: A Single Institution Study
